about
Reduced prostaglandin F2 alpha release from blood mononuclear leukocytes after oral supplementation of omega3 fatty acids: the OmegAD study.Agitation in dementia: relation to core cerebrospinal fluid biomarker levels.Effects of DHA-rich n-3 fatty acid supplementation on gene expression in blood mononuclear leukocytes: the OmegAD study.Effects of n-3 FA supplementation on the release of proresolving lipid mediators by blood mononuclear cells: the OmegAD studyPrevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis.Low background and high contrast PET imaging of amyloid-β with [11C]AZD2995 and [11C]AZD2184 in Alzheimer's disease patients.Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage.Detection of amyloid in Alzheimer's disease with positron emission tomography using [11C]AZD2184.Immunomodulation of microglia by docosahexaenoic acid and eicosapentaenoic acid.Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms.Plasma Fatty Acid Profiles in Relation to Cognition and Gender in Alzheimer's Disease Patients During Oral Omega-3 Fatty Acid Supplementation: The OmegAD Study.The frequency and influence of dementia risk factors in prodromal Alzheimer's disease.Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes.Nutritional Considerations for Healthy Aging and Reduction in Age-Related Chronic Disease.Omega-3 fatty acids enhance phagocytosis of Alzheimer's disease-related amyloid-β42 by human microglia and decrease inflammatory markers.Predicting progression to dementia in persons with mild cognitive impairment using cerebrospinal fluid markers.Omega-3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the omega-3 Alzheimer's disease study.[Omega-3-fatty acids protect against dementia. Also early symptoms of mild Alzheimer disease seem to be inhibited].Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline.Association Between Later Life Lifestyle Factors and Alzheimer's Disease Biomarkers in Non-Demented Individuals: A Longitudinal Descriptive Cohort Study.Effects of omega-3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study.Response to Bogaiksy's letter to the editor.Galantamine versus risperidone treatment of neuropsychiatric symptoms in patients with probable dementia: an open randomized trial.Effects on transthyretin in plasma and cerebrospinal fluid by DHA-rich n - 3 fatty acid supplementation in patients with Alzheimer's disease: the OmegAD study.Neuropsychiatric symptoms in dementia-a role for neuroinflammation?Effects of supplementation with omega-3 fatty acids on oxidative stress and inflammation in patients with Alzheimer's disease: the OmegAD study.Effects of Risperidone and Galantamine Treatment on Alzheimer's Disease Biomarker Levels in Cerebrospinal Fluid.Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial.Does Fatty Acid Composition in Subcutaneous Adipose Tissue Differ between Patients with Alzheimer's Disease and Cohabiting Proxies?Galantamine versus risperidone for agitation in people with dementia: a randomized, twelve-week, single-center study.Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease.Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study.Transfer of omega-3 fatty acids across the blood-brain barrier after dietary supplementation with a docosahexaenoic acid-rich omega-3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study.Effects of docosahexaenoic acid-rich n-3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes: the OmegAD study.Amyloid-β, Tau, and Cognition in Cognitively Normal Older Individuals: Examining the Necessity to Adjust for Biomarker Status in Normative Data.[Administration of symptom-relieving drugs in Alzheimer disease is beneficial]Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling studyPrimary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohortCerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrumA metabolite-based machine learning approach to diagnose Alzheimer-type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort
P50
Q33784535-E4582633-A78F-4DFE-9D41-A9BA398ED96AQ34250065-B2F9CFAB-0922-4B2C-81E4-9B3C1344F434Q34251118-9A2FED3D-01E7-437B-8CAC-989FCD537EFEQ35120950-462BE7E3-E75E-4411-8C42-C78D1834AD86Q35800785-FC4A612D-F289-4F15-B30E-C5CF33F8F5E6Q36662808-6B472FA7-F977-48D6-A8F2-78512BF831AAQ37237863-AC5645A9-5DF9-452E-95DC-34F8B8331FD5Q37392615-62BA910C-82CF-407F-B484-21CA8C3343BAQ37982470-F76BD5AC-D3DE-40E8-B75B-BA8FCAE9338CQ38396432-AA5AC558-A1FF-41AA-AC83-BAEDF75C17F5Q38403214-B7C895B4-A709-4940-8389-9D9973F62510Q38686461-C666DE80-E24C-414A-90D1-BB6C9F54F184Q39036392-50DCD987-B46A-4124-9343-3AA7776D141AQ39092530-E98EC606-5648-451D-BE1D-AA93E4044F84Q39182204-7F374DD4-02BB-49D5-A1B0-5466B9F52E1FQ40327943-D0DE1F49-FD2A-45B7-90FB-BC34A433D024Q46215691-322A0A65-D2B0-4B1C-97F2-ABD3A27DFD1BQ46873169-45AA91C9-A98A-4E1E-8CE6-FFA064B9A9B9Q47560023-45B849FE-BC4B-452C-AF28-4127273F1AEBQ47596108-1B0B1BC8-937E-467C-B5DB-78E353898896Q47806690-69331718-E0CD-4749-B7E5-5E7182DFB4F3Q47833772-29430A3B-961D-4FFC-9FC8-7386CDEDE137Q47979284-B0E01C94-F82F-4935-BFB6-86BA6F40C959Q48093686-117E9D3C-54B1-4E5D-A308-B98DEB93A6A2Q48212656-2E0DCC6A-1D24-4DE2-BC1E-E776414A07FDQ48272484-B6836E78-CFF8-41A2-AA33-D24C9F6B69A4Q48275229-27CB659A-7595-4AE8-AB44-BE9BA9A9AB51Q48400307-E28F8ED2-D149-4B8D-93A9-D495C03F7FD4Q49885017-EBB4DCC3-BCB7-4D6F-AD7A-80BD60B509F2Q51131607-91D46085-B8CC-493C-9863-D62C8F35C06BQ51758135-E855A2E0-C837-452A-BD67-C8E28526965AQ51867713-E36AEF35-C12A-4E53-9369-0AEE67AF5045Q53347902-BBFDAD31-A4BE-446C-BA66-2F468730FFBDQ55050045-27828B2F-2B9C-42CD-A909-B4DC9B9C238EQ55516574-792A1C46-E75F-47AE-AC20-A266C73104D0Q59544469-61929D62-8011-4781-B62C-3976CE89F2E6Q90129599-71FEF28E-DC77-4A41-8443-8F4052DE6320Q91947146-1A9F741B-DF74-4F07-A67F-1AE290B0C667Q92252802-A3B84619-EC64-41C7-BDAD-13508D4690D2Q92345820-BDBBF3D1-0593-475E-9AD1-6D9E180466FD
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Yvonne Freund-Levi
@ast
Yvonne Freund-Levi
@en
Yvonne Freund-Levi
@es
Yvonne Freund-Levi
@nl
Yvonne Freund-Levi
@sl
type
label
Yvonne Freund-Levi
@ast
Yvonne Freund-Levi
@en
Yvonne Freund-Levi
@es
Yvonne Freund-Levi
@nl
Yvonne Freund-Levi
@sl
prefLabel
Yvonne Freund-Levi
@ast
Yvonne Freund-Levi
@en
Yvonne Freund-Levi
@es
Yvonne Freund-Levi
@nl
Yvonne Freund-Levi
@sl
P106
P21
P31
P496
0000-0001-6863-6679
P569
2000-01-01T00:00:00Z